Sign in or create an account to add this stock to your watchlist.
About Neos Therapeutics (NASDAQ:NEOS)
Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older; Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for the treatment of ADHD; and Adzenys ER, an amphetamine XR liquid suspension for the treatment of ADHD. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NEOS
CUSIPN/A
Phone972-408-1300
Debt
Debt-to-Equity Ratio-13.08
Current Ratio1.82
Quick Ratio1.49
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$25.02 million
Price / Sales8.00
Cash FlowN/A
Price / CashN/A
Book Value($0.16) per share
Price / Book-43.13
Profitability
EPS (Most Recent Fiscal Year)($2.68)
Net Income$-66,240,000.00
Net Margins-211.13%
Return on Equity-586.25%
Return on Assets-58.31%
Miscellaneous
Employees138
Outstanding Shares29,000,000
Neos Therapeutics (NASDAQ:NEOS) Frequently Asked Questions
What is Neos Therapeutics' stock symbol?
Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."
How were Neos Therapeutics' earnings last quarter?
Neos Therapeutics (NASDAQ:NEOS) released its earnings results on Wednesday, May, 9th. The company reported ($0.50) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.02. The business earned $10.73 million during the quarter. Neos Therapeutics had a negative return on equity of 586.25% and a negative net margin of 211.13%. View Neos Therapeutics' Earnings History.
When is Neos Therapeutics' next earnings date?
What price target have analysts set for NEOS?
5 equities research analysts have issued twelve-month target prices for Neos Therapeutics' shares. Their predictions range from $12.00 to $20.00. On average, they anticipate Neos Therapeutics' stock price to reach $15.25 in the next twelve months. View Analyst Ratings for Neos Therapeutics.
What are Wall Street analysts saying about Neos Therapeutics stock?
Here are some recent quotes from research analysts about Neos Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, "Positives from the quarter that support our thesis 1) On 01/10/18 NEOS announced that study findings for two of its ADHD medications, ER, were presented in three posters at the upcoming 2018 Annual Meeting of the American Professional Society of ADHD and Related Disorders (APSARD), on 02/20/18 PDL Biopharma (Not Covered) announced termination of interest in acquiring 02/26/18 NEOS announced the U.S. launch of Adzenys ER, making it NEOS’s third ADHD product launch in less than two years; 4) as discussed at the company’s analyst day in March of 2018, NEOS plans to advance its drug candidate for the treatment of nausea and vomiting into the clinic in 2H18 and to identify one additional branded product candidate in CNS or gastroenterology in 2018; and 5) as of 03/31/18 the company held $37.2MM in cash and cash equivalents." (5/9/2018)
- 2. According to Zacks Investment Research, "Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. " (3/22/2018)
Who are some of Neos Therapeutics' key competitors?
Some companies that are related to Neos Therapeutics include Collegium Pharmaceutical (COLL), Deciphera Pharmaceuticals (DCPH), Theratechnologies (THERF), Rocket Pharmaceuticals (RCKT), InflaRx (IFRX), AMAG Pharmaceuticals (AMAG), Adamas Pharmaceuticals (ADMS), Amphastar Pharmaceuticals (AMPH), Abeona Therapeutics (ABEO), GlycoMimetics (GLYC), Vectura Group (VEGPF), ANI Pharmaceuticals Inc Common Stock (ANIP), Homology Medicines (FIXX), Dicerna Pharmaceuticals (DRNA) and CymaBay Therapeutics (CBAY).
Who are Neos Therapeutics' key executives?
Neos Therapeutics' management team includes the folowing people:
- Dr. Vipin K. Garg, CEO, Pres & Director (Age 60)
- Mr. Richard I. Eisenstadt M.B.A., Chief Financial Officer (Age 60)
- Mr. Thomas P. McDonnell, Chief Commercial Officer (Age 46)
- Mr. Russ McMahen, VP of R&D
- Dr. Carolyn R. Sikes Ph.D., VP of Clinical Affairs
When did Neos Therapeutics IPO?
(NEOS) raised $60 million in an initial public offering (IPO) on Thursday, July 23rd 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.
Has Neos Therapeutics been receiving favorable news coverage?
Media headlines about NEOS stock have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Neos Therapeutics earned a media sentiment score of 0.11 on Accern's scale. They also assigned news articles about the company an impact score of 45.04 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Neos Therapeutics' major shareholders?
Neos Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (7.93%), BlackRock Inc. (6.33%), Lyon Street Capital LLC (5.02%), Russell Investments Group Ltd. (2.86%), Cortina Asset Management LLC (2.13%) and Sphera Funds Management LTD. (1.11%). Company insiders that own Neos Therapeutics stock include Bryant Fong, Juergen Martens and Richard I Eisenstadt. View Institutional Ownership Trends for Neos Therapeutics.
Which institutional investors are selling Neos Therapeutics stock?
Which institutional investors are buying Neos Therapeutics stock?
NEOS stock was bought by a variety of institutional investors in the last quarter, including Lyon Street Capital LLC, Russell Investments Group Ltd., Sphera Funds Management LTD., Millennium Management LLC, Allianz Asset Management GmbH, Allianz Asset Management GmbH, Quantitative Systematic Strategies LLC and OMERS ADMINISTRATION Corp. Company insiders that have bought Neos Therapeutics stock in the last two years include Bryant Fong, Juergen Martens and Richard I Eisenstadt. View Insider Buying and Selling for Neos Therapeutics.
How do I buy shares of Neos Therapeutics?
Shares of NEOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neos Therapeutics' stock price today?
One share of NEOS stock can currently be purchased for approximately $6.90.
How big of a company is Neos Therapeutics?
Neos Therapeutics has a market capitalization of $207.33 million and generates $25.02 million in revenue each year. The company earns $-66,240,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Neos Therapeutics employs 138 workers across the globe.
How can I contact Neos Therapeutics?
Neos Therapeutics' mailing address is 2940 NORTH HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300 or via email at [email protected]
MarketBeat Community Rating for Neos Therapeutics (NEOS)
MarketBeat's community ratings are surveys of what our community members think about Neos Therapeutics and other stocks. Vote "Outperform" if you believe NEOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Neos Therapeutics (NASDAQ:NEOS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Neos Therapeutics in the last 12 months. Their average twelve-month price target is $15.25, suggesting that the stock has a possible upside of 121.01%. The high price target for NEOS is $20.00 and the low price target for NEOS is $12.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.80 | 2.80 | 2.67 | 2.83 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $15.25 | $15.25 | $14.8333 | $14.8333 |
| Price Target Upside: | 121.01% upside | 72.90% upside | 33.63% upside | 42.63% upside |
Neos Therapeutics (NASDAQ:NEOS) Consensus Price Target History
Neos Therapeutics (NASDAQ:NEOS) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Neos Therapeutics (NASDAQ:NEOS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Neos Therapeutics (NASDAQ NEOS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.17%
Institutional Ownership Percentage: 52.51%
Neos Therapeutics (NASDAQ NEOS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/31/2016 | Bryant Fong | Director | Buy | 1,500 | $6.54 | $9,810.00 | 1,500 |  |
| 8/25/2016 | Richard I Eisenstadt | CFO | Buy | 3,710 | $6.82 | $25,302.20 | 3,710 | |
| 6/13/2016 | Juergen Martens | Insider | Buy | 10,000 | $9.90 | $99,000.00 | 10,000 | |
| 5/19/2016 | Alan L Heller | Director | Buy | 10,000 | $7.61 | $76,100.00 | 379,888 | |
| 5/19/2016 | Thomas P Mcdonnell | Insider | Buy | 3,000 | $7.56 | $22,680.00 | 3,000 | |
| 5/18/2016 | Gregory J Robitaille | Director | Buy | 7,442 | $7.55 | $56,187.10 | 55,677 | |
| 4/20/2016 | Presidio Partners 2007, L.P. | Major Shareholder | Sell | 20,367 | $9.98 | $203,262.66 | 1,575,419 | |
| 4/15/2016 | Presidio Partners 2007, L.P. | Major Shareholder | Sell | 57,968 | $10.23 | $593,012.64 | 1,623,997 | |
(Data available from 1/1/2013 forward)
Neos Therapeutics (NASDAQ NEOS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Cantor Fitzgerald Analysts Increase Earnings Estimates for Neos Therapeutics (NEOS)
www.americanbankingnews.com - May 24 at 8:34 AM |
 | Should You Be Concerned About Neos Therapeutics Inc’s (NASDAQ:NEOS) Shareholders?
finance.yahoo.com - May 18 at 10:21 AM |
| Neos Therapeutics (NEOS) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - May 15 at 10:14 AM |
| Neos Therapeutics to Present at the UBS Global Healthcare Conference
finance.yahoo.com - May 15 at 9:26 AM |
| Neos Therapeutics (NEOS) Posts Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - May 11 at 8:10 PM |
| Neos Therapeutics (NEOS) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - May 10 at 8:13 PM |
 | Neos Therapeutics misses by $0.03, beats on revenue
seekingalpha.com - May 10 at 9:14 AM |
| Edited Transcript of NEOS earnings conference call or presentation 9-May-18 12:30pm GMT
finance.yahoo.com - May 10 at 9:14 AM |
| Neos Therapeutics' (NEOS) "Buy" Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - May 9 at 6:58 PM |
 | BRIEF-Neos Therapeutics Reports Q1 Loss Per Share $0.50
www.reuters.com - May 9 at 4:52 PM |
| Neos Therapeutics' (NEOS) CEO Vipin Garg on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 4:52 PM |
| Neos Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:06 AM |
| Neos Therapeutics Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 9:06 AM |
| Neos Therapeutics (NEOS) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - May 2 at 11:37 PM |
 | Form 4 Neos Therapeutics, Inc. For: Apr 27 Filed by: Szyper Linda M
www.streetinsider.com - May 2 at 4:51 PM |
| Neos Therapeutics (NEOS) Expected to Announce Earnings of -$0.51 Per Share
www.americanbankingnews.com - May 2 at 11:24 AM |
| Neos Therapeutics to Host First Quarter 2018 Financial Results Conference Call on May 9, 2018
finance.yahoo.com - May 2 at 8:55 AM |
| Neos Therapeutics (NEOS) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 2 at 1:58 AM |
| Research Report Identifies Flexsteel Industries, Second Sight Medical Products, XG Technology, CRA International, Inc, Neos Therapeutics, and Tech Data with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
finance.yahoo.com - May 1 at 8:56 AM |
| Neos Therapeutics (NEOS) Set to Announce Earnings on Monday
www.americanbankingnews.com - April 30 at 12:34 PM |
| Neos Therapeutics (NEOS) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - April 17 at 11:37 AM |
| Zacks: Brokerages Expect Neos Therapeutics (NEOS) Will Announce Earnings of -$0.51 Per Share
www.americanbankingnews.com - April 15 at 11:11 AM |
| Royal Bank of Canada Analysts Give Neos Therapeutics (NEOS) a $12.00 Price Target
www.americanbankingnews.com - April 12 at 11:29 AM |
| Neos Therapeutics (NEOS) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 8 at 11:55 PM |
| Neos Therapeutics Inc (NEOS) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - April 7 at 1:46 AM |
| Neos Therapeutics (NEOS) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 6 at 6:29 PM |
| Zacks Investment Research Downgrades Neos Therapeutics (NEOS) to Sell
www.americanbankingnews.com - April 6 at 1:26 PM |
| Neos Therapeutics (NEOS) Earns "Buy" Rating from Cowen
www.americanbankingnews.com - April 4 at 6:54 PM |
| When Will Neos Therapeutics Inc (NASDAQ:NEOS) Turn A Profit?
finance.yahoo.com - April 4 at 4:40 PM |
| Zacks Investment Research Upgrades Neos Therapeutics (NEOS) to Hold
www.americanbankingnews.com - April 3 at 9:54 PM |
| Neos Therapeutics (NEOS) PT Set at $20.00 by Cantor Fitzgerald
www.americanbankingnews.com - March 30 at 12:05 PM |
| Neos Therapeutics (NEOS) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - March 24 at 6:46 PM |
| Neos Therapeutics (NEOS) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - March 23 at 10:46 PM |
| Neos Therapeutics Inc (NASDAQ:NEOS): Time For A Financial Health Check
finance.yahoo.com - March 23 at 6:14 PM |
| Cantor Fitzgerald Analysts Give Neos Therapeutics (NEOS) a $20.00 Price Target
www.americanbankingnews.com - March 23 at 3:17 PM |
| Neos Therapeutics Inc Forecasted to Post FY2018 Earnings of ($1.86) Per Share (NEOS)
www.americanbankingnews.com - March 23 at 10:38 AM |
| Neos Therapeutics (NEOS) Given a $14.00 Price Target by Wells Fargo Analysts
www.americanbankingnews.com - March 18 at 10:24 AM |
 | Neos Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 17 at 4:58 PM |
| Neos Therapeutics (NEOS) Releases Quarterly Earnings Results, Beats Estimates By $0.12 EPS
www.americanbankingnews.com - March 16 at 8:52 AM |
| Neos Therapeutics (NEOS) Given a $20.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - March 15 at 3:44 PM |
| Neos Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 15 at 10:10 AM |
| Neos Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results
finance.yahoo.com - March 15 at 10:10 AM |
| Are Earnings Prospects Improving For Loss-Making Neos Therapeutics Inc’s (NASDAQ:NEOS)?
finance.yahoo.com - March 15 at 10:10 AM |
| Head to Head Comparison: Histogenics (HSGX) & Neos Therapeutics (NEOS)
www.americanbankingnews.com - March 13 at 9:17 AM |
| Neos Therapeutics Inc (NEOS) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - March 13 at 1:46 AM |
| Neos Therapeutics (NEOS) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 10 at 2:35 PM |
| Neos Therapeutics to Host Fourth Quarter and Year-End 2017 Financial Results Conference Call on March 15, 2017 - GlobeNewswire (press release)
globenewswire.com - March 8 at 4:53 PM |
| Neos Therapeutics to Host Fourth Quarter and Year-End 2017 Financial Results Conference Call on March 15, 2017
finance.yahoo.com - March 8 at 10:20 AM |
| Stonepine Capital Management LLC Buys Shares of 140,000 Neos Therapeutics Inc (NEOS)
www.americanbankingnews.com - March 6 at 10:03 AM |
| Neos Therapeutics to Present at the Cowen & Co. Annual Health Care Conference - GlobeNewswire (press release)
globenewswire.com - March 5 at 4:58 PM |
Neos Therapeutics (NASDAQ:NEOS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Neos Therapeutics (NASDAQ:NEOS) Income Statement, Balance Sheet and Cash Flow Statement
Neos Therapeutics (NASDAQ NEOS) Stock Chart for Saturday, May, 26, 2018
Loading chart…
